The article discusses the role of epigenetics in epithelial-mesenchymal plasticity (EMP) in cancer. It highlights how cancer cells undergo dynamic transitions between epithelial and mesenchymal states, which are regulated by epigenetic mechanisms. These transitions are driven by transcription factors that control gene expression and are influenced by complex epigenetic regulatory mechanisms, including chromatin modifications. The study emphasizes the importance of understanding these interactions to develop new diagnostic and therapeutic strategies for high-grade malignancies. Cancer cells can shift between epithelial and mesenchymal states, a process known as EMP, which is crucial for invasion, metastasis, and the acquisition of stem-like properties. This plasticity is regulated by epigenetic factors, including histone modifications and DNA methylation. The article explores how these epigenetic regulators, such as polycomb repressors, histone deacetylases, and histone demethylases, influence the expression of genes involved in EMT and the maintenance of mesenchymal states. The study also discusses the implications of these epigenetic changes for cancer progression, including the role of EMT in promoting metastasis and the potential for targeting these processes with epigenetic therapies. The article highlights the importance of understanding the epigenetic landscape in cancer cells, including the bivalent modifications and long-term silencing mechanisms, to develop more effective treatments. It concludes that the dynamic nature of EMT and its regulation by epigenetic factors presents new opportunities for therapeutic intervention in cancer.The article discusses the role of epigenetics in epithelial-mesenchymal plasticity (EMP) in cancer. It highlights how cancer cells undergo dynamic transitions between epithelial and mesenchymal states, which are regulated by epigenetic mechanisms. These transitions are driven by transcription factors that control gene expression and are influenced by complex epigenetic regulatory mechanisms, including chromatin modifications. The study emphasizes the importance of understanding these interactions to develop new diagnostic and therapeutic strategies for high-grade malignancies. Cancer cells can shift between epithelial and mesenchymal states, a process known as EMP, which is crucial for invasion, metastasis, and the acquisition of stem-like properties. This plasticity is regulated by epigenetic factors, including histone modifications and DNA methylation. The article explores how these epigenetic regulators, such as polycomb repressors, histone deacetylases, and histone demethylases, influence the expression of genes involved in EMT and the maintenance of mesenchymal states. The study also discusses the implications of these epigenetic changes for cancer progression, including the role of EMT in promoting metastasis and the potential for targeting these processes with epigenetic therapies. The article highlights the importance of understanding the epigenetic landscape in cancer cells, including the bivalent modifications and long-term silencing mechanisms, to develop more effective treatments. It concludes that the dynamic nature of EMT and its regulation by epigenetic factors presents new opportunities for therapeutic intervention in cancer.